| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bone Density | 68 | 2022 | 3469 | 5.260 |
Why?
|
| Osteoporosis | 38 | 2022 | 1581 | 3.290 |
Why?
|
| Menopause | 21 | 2023 | 1621 | 2.530 |
Why?
|
| Teriparatide | 11 | 2014 | 225 | 2.350 |
Why?
|
| Testosterone | 33 | 2020 | 2401 | 2.050 |
Why?
|
| Absorptiometry, Photon | 26 | 2022 | 1726 | 1.990 |
Why?
|
| Osteoporosis, Postmenopausal | 11 | 2016 | 386 | 1.850 |
Why?
|
| Radius | 12 | 2021 | 422 | 1.710 |
Why?
|
| Cystic Fibrosis | 7 | 2022 | 1178 | 1.700 |
Why?
|
| Goserelin | 6 | 2020 | 127 | 1.690 |
Why?
|
| Libido | 4 | 2020 | 121 | 1.640 |
Why?
|
| Estradiol | 23 | 2019 | 2021 | 1.610 |
Why?
|
| Anti-Mullerian Hormone | 3 | 2023 | 399 | 1.500 |
Why?
|
| Bone Density Conservation Agents | 11 | 2022 | 774 | 1.440 |
Why?
|
| Fractures, Bone | 15 | 2022 | 1945 | 1.380 |
Why?
|
| Tibia | 7 | 2018 | 1075 | 1.220 |
Why?
|
| Body Composition | 13 | 2022 | 2400 | 1.110 |
Why?
|
| Bone and Bones | 11 | 2021 | 2575 | 1.100 |
Why?
|
| Fragile X Mental Retardation Protein | 2 | 2016 | 117 | 1.060 |
Why?
|
| Bone Diseases, Metabolic | 6 | 2022 | 417 | 1.050 |
Why?
|
| Leuprolide | 7 | 2017 | 303 | 1.000 |
Why?
|
| Androstenedione | 5 | 2002 | 131 | 1.000 |
Why?
|
| Gonadotropin-Releasing Hormone | 17 | 2017 | 1185 | 0.980 |
Why?
|
| Lumbar Vertebrae | 19 | 2022 | 1844 | 0.900 |
Why?
|
| Women's Health | 17 | 2022 | 2034 | 0.900 |
Why?
|
| Alendronate | 5 | 2010 | 171 | 0.890 |
Why?
|
| Bone Remodeling | 11 | 2018 | 575 | 0.850 |
Why?
|
| Menstrual Cycle | 5 | 2020 | 551 | 0.760 |
Why?
|
| Aminophenols | 1 | 2021 | 78 | 0.750 |
Why?
|
| Vitamin D | 9 | 2019 | 3211 | 0.720 |
Why?
|
| Muscle Strength | 2 | 2013 | 586 | 0.690 |
Why?
|
| Anabolic Agents | 3 | 2010 | 247 | 0.670 |
Why?
|
| Antineoplastic Agents, Hormonal | 8 | 2019 | 1509 | 0.670 |
Why?
|
| Hypogonadism | 14 | 2016 | 798 | 0.660 |
Why?
|
| Premenopause | 10 | 2022 | 1033 | 0.620 |
Why?
|
| Quinolones | 1 | 2021 | 366 | 0.610 |
Why?
|
| Parathyroid Hormone | 10 | 2012 | 1801 | 0.580 |
Why?
|
| Bone Resorption | 7 | 2013 | 722 | 0.570 |
Why?
|
| Eunuchism | 1 | 2016 | 19 | 0.550 |
Why?
|
| Climacteric | 4 | 2004 | 57 | 0.550 |
Why?
|
| Perimenopause | 4 | 2017 | 139 | 0.540 |
Why?
|
| Reproduction | 2 | 2020 | 668 | 0.530 |
Why?
|
| Vitamin D Deficiency | 7 | 2019 | 1331 | 0.520 |
Why?
|
| Femur Neck | 9 | 2022 | 309 | 0.510 |
Why?
|
| Ergocalciferols | 2 | 2015 | 110 | 0.510 |
Why?
|
| Middle Aged | 96 | 2022 | 213127 | 0.500 |
Why?
|
| Aromatase Inhibitors | 6 | 2019 | 491 | 0.500 |
Why?
|
| Prescriptions | 2 | 2021 | 387 | 0.490 |
Why?
|
| Postmenopause | 8 | 2021 | 2461 | 0.490 |
Why?
|
| Histamine H2 Antagonists | 1 | 2015 | 165 | 0.460 |
Why?
|
| Follicle Stimulating Hormone, Human | 1 | 2013 | 25 | 0.460 |
Why?
|
| Fibroblast Growth Factors | 2 | 2012 | 879 | 0.450 |
Why?
|
| Adult | 95 | 2022 | 213712 | 0.450 |
Why?
|
| Hormones | 7 | 2017 | 884 | 0.450 |
Why?
|
| Nafarelin | 4 | 1999 | 27 | 0.420 |
Why?
|
| Spinal Neoplasms | 6 | 2015 | 759 | 0.420 |
Why?
|
| Female | 108 | 2023 | 379592 | 0.400 |
Why?
|
| Fractures, Spontaneous | 10 | 2017 | 230 | 0.400 |
Why?
|
| Bone Cements | 4 | 2006 | 325 | 0.400 |
Why?
|
| Adipose Tissue | 4 | 2022 | 3278 | 0.400 |
Why?
|
| Puberty, Delayed | 3 | 1999 | 115 | 0.390 |
Why?
|
| Adiposity | 2 | 2020 | 1806 | 0.390 |
Why?
|
| Spinal Fractures | 7 | 2011 | 698 | 0.380 |
Why?
|
| Menstruation | 5 | 2020 | 299 | 0.380 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2019 | 1573 | 0.380 |
Why?
|
| Gonadotropins | 6 | 1991 | 241 | 0.380 |
Why?
|
| Humans | 161 | 2023 | 742088 | 0.380 |
Why?
|
| Obesity, Morbid | 3 | 2018 | 1204 | 0.370 |
Why?
|
| Infertility, Female | 1 | 2016 | 784 | 0.370 |
Why?
|
| Gastric Bypass | 2 | 2018 | 812 | 0.370 |
Why?
|
| Polymethyl Methacrylate | 3 | 2006 | 145 | 0.360 |
Why?
|
| Drug Utilization | 2 | 2016 | 1181 | 0.360 |
Why?
|
| Follicle Stimulating Hormone | 16 | 2019 | 738 | 0.360 |
Why?
|
| Spinal Cord Compression | 2 | 2015 | 235 | 0.360 |
Why?
|
| Antihypertensive Agents | 2 | 2019 | 2043 | 0.360 |
Why?
|
| Proton Pump Inhibitors | 1 | 2015 | 521 | 0.360 |
Why?
|
| Prostatic Neoplasms | 11 | 2011 | 11039 | 0.350 |
Why?
|
| Longitudinal Studies | 23 | 2020 | 13921 | 0.340 |
Why?
|
| Tomography, X-Ray Computed | 15 | 2018 | 20086 | 0.340 |
Why?
|
| Male | 96 | 2022 | 349538 | 0.330 |
Why?
|
| Prescription Drugs | 1 | 2016 | 595 | 0.330 |
Why?
|
| Cohort Studies | 29 | 2021 | 40450 | 0.330 |
Why?
|
| Estrogens | 5 | 2017 | 1562 | 0.330 |
Why?
|
| Phosphates | 3 | 2012 | 786 | 0.330 |
Why?
|
| Peptide Fragments | 3 | 2019 | 5095 | 0.310 |
Why?
|
| Orthopedic Procedures | 3 | 2008 | 1288 | 0.310 |
Why?
|
| Decompression, Surgical | 2 | 2014 | 593 | 0.310 |
Why?
|
| Osteocalcin | 7 | 2012 | 273 | 0.310 |
Why?
|
| Injections, Subcutaneous | 4 | 2020 | 664 | 0.300 |
Why?
|
| Gonadal Steroid Hormones | 9 | 2014 | 711 | 0.300 |
Why?
|
| Androgens | 5 | 2019 | 1271 | 0.290 |
Why?
|
| Spinal Osteophytosis | 1 | 2006 | 29 | 0.290 |
Why?
|
| Spinal Canal | 1 | 2006 | 39 | 0.290 |
Why?
|
| Spine | 9 | 2018 | 1143 | 0.290 |
Why?
|
| Osteoporotic Fractures | 2 | 2022 | 403 | 0.280 |
Why?
|
| Dietary Supplements | 6 | 2019 | 3294 | 0.280 |
Why?
|
| Selective Estrogen Receptor Modulators | 2 | 2017 | 129 | 0.270 |
Why?
|
| Health Behavior | 2 | 2016 | 2630 | 0.270 |
Why?
|
| Spinal Fusion | 3 | 2014 | 1234 | 0.260 |
Why?
|
| Laminectomy | 1 | 2006 | 232 | 0.260 |
Why?
|
| Nitriles | 3 | 2005 | 952 | 0.260 |
Why?
|
| Aging | 5 | 2020 | 8626 | 0.260 |
Why?
|
| Trinucleotide Repeats | 2 | 2016 | 261 | 0.260 |
Why?
|
| Aged | 50 | 2021 | 162944 | 0.260 |
Why?
|
| Pain, Intractable | 1 | 2006 | 130 | 0.250 |
Why?
|
| Patient Compliance | 6 | 2017 | 2680 | 0.250 |
Why?
|
| Dose-Response Relationship, Drug | 11 | 2020 | 10943 | 0.250 |
Why?
|
| Bone Development | 5 | 2005 | 483 | 0.250 |
Why?
|
| Bone Neoplasms | 6 | 2017 | 2522 | 0.250 |
Why?
|
| Ovary | 3 | 2023 | 981 | 0.240 |
Why?
|
| Bariatric Surgery | 1 | 2014 | 940 | 0.240 |
Why?
|
| Vitamins | 2 | 2012 | 1608 | 0.240 |
Why?
|
| Follow-Up Studies | 15 | 2022 | 39004 | 0.240 |
Why?
|
| Diphosphonates | 4 | 2007 | 625 | 0.240 |
Why?
|
| Case-Control Studies | 7 | 2022 | 21719 | 0.240 |
Why?
|
| Hypoglycemic Agents | 1 | 2016 | 2866 | 0.230 |
Why?
|
| Spinal Diseases | 2 | 2008 | 538 | 0.230 |
Why?
|
| Triazoles | 3 | 2014 | 907 | 0.230 |
Why?
|
| Insulin Resistance | 5 | 2022 | 3861 | 0.220 |
Why?
|
| Epitestosterone | 1 | 2002 | 3 | 0.220 |
Why?
|
| United States | 22 | 2021 | 69693 | 0.210 |
Why?
|
| Aged, 80 and over | 24 | 2020 | 57683 | 0.210 |
Why?
|
| Endometriosis | 3 | 1999 | 834 | 0.210 |
Why?
|
| Administration, Cutaneous | 2 | 2020 | 711 | 0.210 |
Why?
|
| Overweight | 1 | 2013 | 2366 | 0.200 |
Why?
|
| Collagen Type I | 6 | 2014 | 592 | 0.200 |
Why?
|
| Anilides | 1 | 2004 | 404 | 0.200 |
Why?
|
| Estranes | 1 | 2000 | 2 | 0.200 |
Why?
|
| Nandrolone | 1 | 2000 | 17 | 0.190 |
Why?
|
| Calcium | 5 | 2006 | 5753 | 0.190 |
Why?
|
| Penile Erection | 1 | 2020 | 97 | 0.180 |
Why?
|
| Practice Guidelines as Topic | 4 | 2012 | 7276 | 0.180 |
Why?
|
| Cervical Vertebrae | 1 | 2006 | 973 | 0.180 |
Why?
|
| Young Adult | 12 | 2022 | 56350 | 0.180 |
Why?
|
| Prospective Studies | 12 | 2022 | 53187 | 0.180 |
Why?
|
| Nonprescription Drugs | 1 | 2000 | 116 | 0.180 |
Why?
|
| Luteinizing Hormone | 13 | 2017 | 864 | 0.170 |
Why?
|
| Drug Contamination | 1 | 2000 | 148 | 0.170 |
Why?
|
| Gels | 1 | 2020 | 427 | 0.170 |
Why?
|
| Chromatography, Liquid | 2 | 2014 | 977 | 0.170 |
Why?
|
| Body Fat Distribution | 1 | 2020 | 244 | 0.170 |
Why?
|
| Treatment Outcome | 20 | 2020 | 62966 | 0.160 |
Why?
|
| Body Mass Index | 9 | 2022 | 12695 | 0.160 |
Why?
|
| Drug Therapy, Combination | 3 | 2020 | 6483 | 0.160 |
Why?
|
| Mass Screening | 2 | 2012 | 5238 | 0.160 |
Why?
|
| Hip | 2 | 2021 | 257 | 0.160 |
Why?
|
| Reference Values | 5 | 2016 | 4982 | 0.160 |
Why?
|
| Body Weight | 4 | 2019 | 4664 | 0.160 |
Why?
|
| Computer Simulation | 1 | 2012 | 6191 | 0.160 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2021 | 437 | 0.160 |
Why?
|
| Administration, Topical | 1 | 2019 | 688 | 0.150 |
Why?
|
| Spinal Cord Injuries | 2 | 2015 | 930 | 0.150 |
Why?
|
| Tandem Mass Spectrometry | 2 | 2014 | 1157 | 0.140 |
Why?
|
| Estrone | 4 | 2017 | 239 | 0.140 |
Why?
|
| Prediabetic State | 1 | 2022 | 493 | 0.140 |
Why?
|
| Orthopedics | 3 | 2022 | 903 | 0.140 |
Why?
|
| Blood Chemical Analysis | 2 | 2014 | 440 | 0.140 |
Why?
|
| Amino Acid Substitution | 1 | 2021 | 1792 | 0.140 |
Why?
|
| Galactose | 1 | 2017 | 306 | 0.130 |
Why?
|
| Immunoassay | 2 | 2012 | 752 | 0.130 |
Why?
|
| Sodium Chloride Symporter Inhibitors | 1 | 2015 | 76 | 0.130 |
Why?
|
| Receptors, Histamine H2 | 1 | 2015 | 18 | 0.130 |
Why?
|
| Patient Satisfaction | 1 | 2008 | 3391 | 0.130 |
Why?
|
| Time Factors | 11 | 2015 | 40054 | 0.130 |
Why?
|
| Femur | 3 | 2012 | 1297 | 0.130 |
Why?
|
| Collagen | 4 | 2013 | 2684 | 0.130 |
Why?
|
| Calcitriol | 3 | 2006 | 298 | 0.130 |
Why?
|
| Eating | 1 | 2022 | 1535 | 0.130 |
Why?
|
| Pituitary Hormone-Releasing Hormones | 3 | 1990 | 41 | 0.130 |
Why?
|
| Hormone Replacement Therapy | 2 | 2015 | 744 | 0.130 |
Why?
|
| Cross-Sectional Studies | 9 | 2022 | 24913 | 0.120 |
Why?
|
| 24,25-Dihydroxyvitamin D 3 | 1 | 2014 | 9 | 0.120 |
Why?
|
| Androgen Antagonists | 3 | 2011 | 1350 | 0.120 |
Why?
|
| Urinalysis | 3 | 2002 | 369 | 0.120 |
Why?
|
| Tibial Fractures | 1 | 2017 | 269 | 0.120 |
Why?
|
| Glycosylation | 1 | 2017 | 1123 | 0.120 |
Why?
|
| Multivariate Analysis | 6 | 2014 | 12242 | 0.110 |
Why?
|
| Osteogenesis | 3 | 2014 | 1299 | 0.110 |
Why?
|
| Patient Education as Topic | 3 | 2008 | 2275 | 0.110 |
Why?
|
| Drug Monitoring | 1 | 2019 | 956 | 0.110 |
Why?
|
| Propensity Score | 2 | 2019 | 1771 | 0.110 |
Why?
|
| Motor Activity | 3 | 2014 | 2714 | 0.110 |
Why?
|
| Spondylolisthesis | 1 | 2014 | 162 | 0.110 |
Why?
|
| Sex Hormone-Binding Globulin | 6 | 2019 | 548 | 0.100 |
Why?
|
| Drug Combinations | 2 | 2009 | 1961 | 0.100 |
Why?
|
| Peptides | 6 | 2014 | 4392 | 0.100 |
Why?
|
| Obesity | 2 | 2019 | 12705 | 0.100 |
Why?
|
| Adolescent | 15 | 2022 | 85649 | 0.100 |
Why?
|
| Risk Factors | 13 | 2019 | 72145 | 0.100 |
Why?
|
| Alkaline Phosphatase | 3 | 2003 | 865 | 0.100 |
Why?
|
| Administration, Oral | 4 | 2002 | 3913 | 0.100 |
Why?
|
| Mutation, Missense | 1 | 2021 | 2556 | 0.100 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 2013 | 434 | 0.100 |
Why?
|
| Hypercalcemia | 1 | 2014 | 405 | 0.100 |
Why?
|
| Finite Element Analysis | 1 | 2013 | 431 | 0.100 |
Why?
|
| Sex Factors | 6 | 2017 | 10392 | 0.100 |
Why?
|
| Weight-Bearing | 1 | 2013 | 514 | 0.100 |
Why?
|
| Fertility | 1 | 2016 | 770 | 0.100 |
Why?
|
| Japan | 2 | 2013 | 1360 | 0.090 |
Why?
|
| Prognosis | 4 | 2020 | 29010 | 0.090 |
Why?
|
| Polysaccharides | 1 | 2017 | 1051 | 0.090 |
Why?
|
| Diet | 2 | 2006 | 7923 | 0.090 |
Why?
|
| Pituitary Gland | 4 | 1989 | 665 | 0.090 |
Why?
|
| Fractures, Compression | 1 | 2011 | 134 | 0.090 |
Why?
|
| Age Factors | 7 | 2015 | 18355 | 0.090 |
Why?
|
| Logistic Models | 5 | 2019 | 13403 | 0.090 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2015 | 1239 | 0.090 |
Why?
|
| Gene Frequency | 1 | 2016 | 3587 | 0.090 |
Why?
|
| Risk | 3 | 2019 | 9679 | 0.080 |
Why?
|
| Blood Glucose | 4 | 2022 | 6249 | 0.080 |
Why?
|
| Procollagen | 2 | 2006 | 185 | 0.080 |
Why?
|
| China | 2 | 2013 | 2246 | 0.080 |
Why?
|
| Substance Abuse Detection | 2 | 2002 | 283 | 0.080 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2015 | 1517 | 0.080 |
Why?
|
| Embalming | 1 | 1988 | 13 | 0.080 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2008 | 3915 | 0.080 |
Why?
|
| Odds Ratio | 2 | 2016 | 9846 | 0.080 |
Why?
|
| Pelvic Bones | 2 | 2018 | 265 | 0.080 |
Why?
|
| Risk Assessment | 6 | 2019 | 23320 | 0.080 |
Why?
|
| Boston | 4 | 2015 | 9305 | 0.080 |
Why?
|
| Gynecomastia | 1 | 1988 | 88 | 0.080 |
Why?
|
| Anthropometry | 2 | 2002 | 1350 | 0.080 |
Why?
|
| Retreatment | 1 | 2009 | 604 | 0.080 |
Why?
|
| Chorionic Gonadotropin | 1 | 1989 | 474 | 0.080 |
Why?
|
| Linear Models | 3 | 2014 | 5948 | 0.070 |
Why?
|
| Versicans | 1 | 2007 | 33 | 0.070 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2016 | 11695 | 0.070 |
Why?
|
| Pharmacoepidemiology | 2 | 2019 | 323 | 0.070 |
Why?
|
| Antidepressive Agents | 1 | 2019 | 2838 | 0.070 |
Why?
|
| Area Under Curve | 2 | 2002 | 1653 | 0.070 |
Why?
|
| Genetic Association Studies | 1 | 2016 | 2699 | 0.070 |
Why?
|
| Weight Gain | 2 | 2019 | 2282 | 0.070 |
Why?
|
| Cyclic AMP | 1 | 2010 | 1470 | 0.070 |
Why?
|
| Seasons | 1 | 2012 | 1492 | 0.070 |
Why?
|
| Quality of Life | 4 | 2006 | 12730 | 0.070 |
Why?
|
| Hyperparathyroidism, Primary | 1 | 2008 | 155 | 0.070 |
Why?
|
| Body Constitution | 2 | 2004 | 278 | 0.070 |
Why?
|
| Exercise | 2 | 2022 | 5611 | 0.070 |
Why?
|
| Patient Care Team | 1 | 2017 | 2527 | 0.070 |
Why?
|
| Endocrinology | 1 | 2012 | 443 | 0.070 |
Why?
|
| Socioeconomic Factors | 2 | 2019 | 7770 | 0.070 |
Why?
|
| Physicians, Family | 1 | 2007 | 345 | 0.070 |
Why?
|
| Aromatase | 1 | 2005 | 146 | 0.070 |
Why?
|
| Bone Diseases | 1 | 2009 | 416 | 0.060 |
Why?
|
| Chi-Square Distribution | 1 | 2012 | 3510 | 0.060 |
Why?
|
| Canada | 3 | 2015 | 2061 | 0.060 |
Why?
|
| Drug Interactions | 1 | 2010 | 1458 | 0.060 |
Why?
|
| Immunoglobulin G | 1 | 2017 | 4554 | 0.060 |
Why?
|
| Anorexia Nervosa | 1 | 2014 | 1286 | 0.060 |
Why?
|
| Palliative Care | 4 | 2017 | 3478 | 0.060 |
Why?
|
| Length of Stay | 2 | 2015 | 6294 | 0.060 |
Why?
|
| Osteoprotegerin | 1 | 2005 | 176 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2016 | 17400 | 0.060 |
Why?
|
| Pennsylvania | 4 | 2008 | 613 | 0.060 |
Why?
|
| Tosyl Compounds | 1 | 2004 | 110 | 0.060 |
Why?
|
| Prostate-Specific Antigen | 3 | 2011 | 2458 | 0.060 |
Why?
|
| Waist Circumference | 2 | 2021 | 917 | 0.060 |
Why?
|
| Phantoms, Imaging | 1 | 2012 | 2466 | 0.060 |
Why?
|
| Weight Loss | 1 | 2015 | 2604 | 0.060 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 3862 | 0.060 |
Why?
|
| Pain | 3 | 2016 | 4961 | 0.060 |
Why?
|
| Extravasation of Diagnostic and Therapeutic Materials | 1 | 2003 | 105 | 0.050 |
Why?
|
| Pregnanediol | 2 | 2017 | 18 | 0.050 |
Why?
|
| Control Groups | 1 | 2002 | 105 | 0.050 |
Why?
|
| Androsterone | 2 | 2001 | 14 | 0.050 |
Why?
|
| Etiocholanolone | 2 | 2001 | 7 | 0.050 |
Why?
|
| Patient Selection | 3 | 2015 | 4214 | 0.050 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2005 | 595 | 0.050 |
Why?
|
| Recovery of Function | 2 | 2014 | 2924 | 0.050 |
Why?
|
| Estrogen Replacement Therapy | 2 | 2006 | 1202 | 0.050 |
Why?
|
| Corpus Luteum | 2 | 2017 | 86 | 0.050 |
Why?
|
| Adiponectin | 1 | 2008 | 1099 | 0.050 |
Why?
|
| Medicare | 2 | 2012 | 6532 | 0.050 |
Why?
|
| Pain Measurement | 2 | 2016 | 3418 | 0.050 |
Why?
|
| Glucuronides | 1 | 2001 | 20 | 0.050 |
Why?
|
| Calcifediol | 2 | 2015 | 166 | 0.050 |
Why?
|
| Antineoplastic Agents | 2 | 2004 | 13655 | 0.050 |
Why?
|
| Syndrome | 1 | 2008 | 3248 | 0.050 |
Why?
|
| Guideline Adherence | 1 | 2012 | 2266 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2016 | 3336 | 0.050 |
Why?
|
| Hip Joint | 3 | 2014 | 1002 | 0.050 |
Why?
|
| Drug Administration Schedule | 5 | 2007 | 4929 | 0.050 |
Why?
|
| Propylamines | 3 | 1966 | 165 | 0.050 |
Why?
|
| Infusions, Intravenous | 3 | 2007 | 2271 | 0.050 |
Why?
|
| HIV Wasting Syndrome | 1 | 2001 | 97 | 0.050 |
Why?
|
| Dihydrotestosterone | 1 | 2001 | 188 | 0.050 |
Why?
|
| Safety | 1 | 2006 | 1185 | 0.050 |
Why?
|
| Sodium | 1 | 2006 | 1627 | 0.050 |
Why?
|
| Imidazoles | 1 | 2007 | 1205 | 0.050 |
Why?
|
| Life Style | 2 | 2002 | 3824 | 0.050 |
Why?
|
| Monoamine Oxidase Inhibitors | 3 | 1966 | 158 | 0.050 |
Why?
|
| Insulin | 1 | 2015 | 6575 | 0.050 |
Why?
|
| Disability Evaluation | 1 | 2008 | 1827 | 0.050 |
Why?
|
| Biopsy, Needle | 1 | 2006 | 1640 | 0.050 |
Why?
|
| Depressive Disorder | 1 | 2013 | 3748 | 0.050 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2005 | 867 | 0.050 |
Why?
|
| Ovariectomy | 1 | 2023 | 660 | 0.050 |
Why?
|
| Evidence-Based Medicine | 1 | 2012 | 3611 | 0.050 |
Why?
|
| Family Practice | 1 | 2003 | 516 | 0.040 |
Why?
|
| New England | 1 | 2003 | 1021 | 0.040 |
Why?
|
| Calcium Gluconate | 1 | 1999 | 23 | 0.040 |
Why?
|
| Occupational Diseases | 1 | 1988 | 1472 | 0.040 |
Why?
|
| Severity of Illness Index | 4 | 2015 | 15530 | 0.040 |
Why?
|
| Pirenzepine | 1 | 1999 | 115 | 0.040 |
Why?
|
| Blood Pressure | 3 | 2019 | 8541 | 0.040 |
Why?
|
| Thoracic Vertebrae | 1 | 2004 | 604 | 0.040 |
Why?
|
| Phenotype | 2 | 2016 | 16331 | 0.040 |
Why?
|
| Inpatients | 2 | 2022 | 2495 | 0.040 |
Why?
|
| Data Interpretation, Statistical | 2 | 2006 | 2714 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2011 | 9185 | 0.040 |
Why?
|
| Health Maintenance Organizations | 1 | 2001 | 642 | 0.040 |
Why?
|
| Joint Instability | 1 | 2006 | 792 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2003 | 1791 | 0.040 |
Why?
|
| Lipids | 2 | 2008 | 3302 | 0.040 |
Why?
|
| Calcium, Dietary | 1 | 2001 | 527 | 0.040 |
Why?
|
| Incidence | 2 | 2015 | 20928 | 0.040 |
Why?
|
| Extremities | 2 | 2017 | 865 | 0.040 |
Why?
|
| Protein Precursors | 1 | 2002 | 1154 | 0.040 |
Why?
|
| Attitude to Health | 1 | 2007 | 2051 | 0.040 |
Why?
|
| Sexual Behavior, Animal | 1 | 1978 | 113 | 0.040 |
Why?
|
| Feedback | 2 | 1991 | 793 | 0.040 |
Why?
|
| Diet Surveys | 1 | 2022 | 1172 | 0.040 |
Why?
|
| Medication Adherence | 1 | 2009 | 2055 | 0.040 |
Why?
|
| Hip Fractures | 1 | 2006 | 954 | 0.040 |
Why?
|
| Pineal Gland | 1 | 1978 | 165 | 0.040 |
Why?
|
| Referral and Consultation | 2 | 2017 | 3527 | 0.040 |
Why?
|
| Karnofsky Performance Status | 1 | 2017 | 173 | 0.040 |
Why?
|
| Retrospective Studies | 9 | 2021 | 77098 | 0.040 |
Why?
|
| Double-Blind Method | 3 | 2015 | 12017 | 0.040 |
Why?
|
| Aldehyde Oxidoreductases | 1 | 1997 | 88 | 0.040 |
Why?
|
| Glycoproteins | 1 | 2005 | 2260 | 0.040 |
Why?
|
| Sodium Oxybate | 1 | 1997 | 32 | 0.040 |
Why?
|
| Hysterectomy | 1 | 2023 | 927 | 0.040 |
Why?
|
| Fertility Agents, Female | 1 | 2017 | 99 | 0.040 |
Why?
|
| Accidental Falls | 2 | 2019 | 1057 | 0.040 |
Why?
|
| Sports | 1 | 2003 | 686 | 0.040 |
Why?
|
| Ontario | 1 | 2017 | 381 | 0.040 |
Why?
|
| C-Reactive Protein | 1 | 2008 | 3766 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 1 | 2001 | 1661 | 0.030 |
Why?
|
| Sunlight | 1 | 1998 | 325 | 0.030 |
Why?
|
| Intra-Abdominal Fat | 1 | 2021 | 591 | 0.030 |
Why?
|
| Secondary Prevention | 1 | 2022 | 1520 | 0.030 |
Why?
|
| Diabetic Ketoacidosis | 1 | 1999 | 247 | 0.030 |
Why?
|
| 25-Hydroxyvitamin D 2 | 1 | 2015 | 39 | 0.030 |
Why?
|
| Estrogens, Conjugated (USP) | 1 | 2017 | 275 | 0.030 |
Why?
|
| Iproniazid | 2 | 1966 | 8 | 0.030 |
Why?
|
| Light | 2 | 1978 | 1374 | 0.030 |
Why?
|
| Abbreviated Injury Scale | 1 | 2014 | 51 | 0.030 |
Why?
|
| Amino Acids | 1 | 2001 | 1727 | 0.030 |
Why?
|
| Iodine Radioisotopes | 2 | 1989 | 1030 | 0.030 |
Why?
|
| Gonads | 1 | 2014 | 107 | 0.030 |
Why?
|
| Radionuclide Imaging | 2 | 1989 | 2027 | 0.030 |
Why?
|
| Enzyme Inhibitors | 2 | 2003 | 3800 | 0.030 |
Why?
|
| Porosity | 1 | 2014 | 362 | 0.030 |
Why?
|
| Child | 4 | 2021 | 77478 | 0.030 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2009 | 3695 | 0.030 |
Why?
|
| Health Services Research | 1 | 2001 | 1834 | 0.030 |
Why?
|
| Osteolysis | 2 | 2007 | 270 | 0.030 |
Why?
|
| Adenocarcinoma | 1 | 2011 | 6347 | 0.030 |
Why?
|
| Dehydroepiandrosterone Sulfate | 2 | 2005 | 238 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 2000 | 2203 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2001 | 2906 | 0.030 |
Why?
|
| Self Efficacy | 2 | 2008 | 610 | 0.030 |
Why?
|
| Thyrotropin | 2 | 2003 | 850 | 0.030 |
Why?
|
| Radioimmunoassay | 3 | 1989 | 918 | 0.030 |
Why?
|
| Quinoxalines | 1 | 2014 | 288 | 0.030 |
Why?
|
| Testolactone | 1 | 1991 | 7 | 0.030 |
Why?
|
| Diabetes Complications | 1 | 1999 | 1359 | 0.030 |
Why?
|
| Calibration | 1 | 1994 | 815 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2017 | 1839 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2017 | 1769 | 0.030 |
Why?
|
| Glucocorticoids | 2 | 2008 | 2107 | 0.030 |
Why?
|
| Pulmonary Embolism | 1 | 2004 | 2370 | 0.020 |
Why?
|
| Human Growth Hormone | 1 | 1996 | 683 | 0.020 |
Why?
|
| Respiratory Function Tests | 1 | 2015 | 1613 | 0.020 |
Why?
|
| Predictive Value of Tests | 3 | 2014 | 15056 | 0.020 |
Why?
|
| Glycoprotein Hormones, alpha Subunit | 1 | 1990 | 98 | 0.020 |
Why?
|
| Postoperative Care | 1 | 2017 | 1484 | 0.020 |
Why?
|
| Women | 1 | 2012 | 230 | 0.020 |
Why?
|
| Medical Records | 1 | 1996 | 1413 | 0.020 |
Why?
|
| Breast Neoplasms | 3 | 2010 | 20774 | 0.020 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2005 | 3239 | 0.020 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 2014 | 2014 | 0.020 |
Why?
|
| Iodobenzoates | 1 | 1989 | 10 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 1998 | 6365 | 0.020 |
Why?
|
| Neurosecretory Systems | 1 | 1991 | 231 | 0.020 |
Why?
|
| Radiography | 2 | 2011 | 7010 | 0.020 |
Why?
|
| Triiodobenzoic Acids | 1 | 1989 | 123 | 0.020 |
Why?
|
| Age Distribution | 2 | 2005 | 2900 | 0.020 |
Why?
|
| Fracture Healing | 1 | 2011 | 426 | 0.020 |
Why?
|
| Periodicity | 4 | 1990 | 363 | 0.020 |
Why?
|
| Prevalence | 2 | 2012 | 15194 | 0.020 |
Why?
|
| Testis | 2 | 1989 | 800 | 0.020 |
Why?
|
| Algorithms | 1 | 2009 | 13853 | 0.020 |
Why?
|
| Viscera | 1 | 1989 | 139 | 0.020 |
Why?
|
| Fasting | 1 | 2014 | 1589 | 0.020 |
Why?
|
| Gonadotropins, Pituitary | 1 | 1988 | 73 | 0.020 |
Why?
|
| Technetium Tc 99m Sestamibi | 1 | 2008 | 176 | 0.020 |
Why?
|
| Infusion Pumps | 1 | 1988 | 163 | 0.020 |
Why?
|
| Reoperation | 1 | 2017 | 4200 | 0.020 |
Why?
|
| Etidronic Acid | 1 | 2007 | 64 | 0.020 |
Why?
|
| Sleep | 2 | 2021 | 4604 | 0.020 |
Why?
|
| Parathyroid Neoplasms | 1 | 2008 | 245 | 0.020 |
Why?
|
| Isocarboxazid | 1 | 1966 | 7 | 0.020 |
Why?
|
| Tranylcypromine | 1 | 1966 | 29 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2017 | 4839 | 0.020 |
Why?
|
| Primary Health Care | 1 | 2003 | 4551 | 0.020 |
Why?
|
| Antipsychotic Agents | 1 | 1999 | 3058 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 1988 | 1420 | 0.020 |
Why?
|
| Body Height | 1 | 2012 | 1574 | 0.020 |
Why?
|
| Calcitonin | 1 | 2007 | 336 | 0.020 |
Why?
|
| Compressive Strength | 1 | 2006 | 169 | 0.020 |
Why?
|
| Sexual Maturation | 1 | 1986 | 265 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2014 | 6452 | 0.020 |
Why?
|
| Chickens | 1 | 2007 | 865 | 0.020 |
Why?
|
| Densitometry | 1 | 2004 | 156 | 0.020 |
Why?
|
| Educational Status | 1 | 2012 | 2533 | 0.020 |
Why?
|
| Hand | 1 | 2009 | 882 | 0.010 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2008 | 1107 | 0.010 |
Why?
|
| Angiography | 1 | 1989 | 1636 | 0.010 |
Why?
|
| Lung | 1 | 2022 | 9826 | 0.010 |
Why?
|
| Polypharmacy | 1 | 2005 | 294 | 0.010 |
Why?
|
| Fibronectins | 1 | 2007 | 723 | 0.010 |
Why?
|
| Consensus | 1 | 2012 | 2935 | 0.010 |
Why?
|
| Pharmacology | 1 | 1963 | 103 | 0.010 |
Why?
|
| Body Weights and Measures | 1 | 2003 | 211 | 0.010 |
Why?
|
| Prostate | 1 | 2011 | 1764 | 0.010 |
Why?
|
| Monoamine Oxidase | 1 | 1963 | 178 | 0.010 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2011 | 3471 | 0.010 |
Why?
|
| Toxicology | 1 | 1963 | 106 | 0.010 |
Why?
|
| Treatment Refusal | 1 | 2005 | 416 | 0.010 |
Why?
|
| Prostatectomy | 1 | 2011 | 1871 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2014 | 8621 | 0.010 |
Why?
|
| Cadaver | 1 | 2006 | 1333 | 0.010 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 1963 | 282 | 0.010 |
Why?
|
| Metabolism | 1 | 1963 | 193 | 0.010 |
Why?
|
| Mesocricetus | 2 | 1978 | 251 | 0.010 |
Why?
|
| Cross-Over Studies | 1 | 2007 | 2030 | 0.010 |
Why?
|
| Hospital Mortality | 1 | 2015 | 5310 | 0.010 |
Why?
|
| Hydrazines | 1 | 1963 | 220 | 0.010 |
Why?
|
| Survival Rate | 1 | 2015 | 12773 | 0.010 |
Why?
|
| Economics, Pharmaceutical | 1 | 2001 | 87 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2003 | 15244 | 0.010 |
Why?
|
| Injections | 1 | 2004 | 840 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 1999 | 5724 | 0.010 |
Why?
|
| Physical Endurance | 1 | 2003 | 370 | 0.010 |
Why?
|
| Sex Distribution | 1 | 2005 | 2295 | 0.010 |
Why?
|
| Mice, Nude | 1 | 2007 | 3689 | 0.010 |
Why?
|
| Cell Adhesion | 1 | 2007 | 3139 | 0.010 |
Why?
|
| Receptors, Estrogen | 1 | 1988 | 2186 | 0.010 |
Why?
|
| Registries | 1 | 2015 | 8077 | 0.010 |
Why?
|
| Community Networks | 1 | 2001 | 203 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2007 | 3847 | 0.010 |
Why?
|
| Societies, Medical | 1 | 2011 | 3740 | 0.010 |
Why?
|
| Antirheumatic Agents | 1 | 2009 | 1335 | 0.010 |
Why?
|
| Alcohol Drinking | 1 | 2012 | 3957 | 0.010 |
Why?
|
| Databases as Topic | 1 | 2001 | 475 | 0.010 |
Why?
|
| Rats | 2 | 1988 | 24265 | 0.010 |
Why?
|
| Biopsy | 1 | 2011 | 6756 | 0.010 |
Why?
|
| Copulation | 1 | 1978 | 11 | 0.010 |
Why?
|
| Disease Progression | 1 | 2015 | 13256 | 0.010 |
Why?
|
| Health Surveys | 1 | 2009 | 4030 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2014 | 14554 | 0.010 |
Why?
|
| Estrus | 1 | 1978 | 82 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2006 | 35342 | 0.010 |
Why?
|
| Castration | 1 | 1978 | 158 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 2007 | 3612 | 0.010 |
Why?
|
| Proteins | 1 | 2014 | 6096 | 0.010 |
Why?
|
| Stress, Mechanical | 1 | 2004 | 1684 | 0.010 |
Why?
|
| Transfection | 1 | 2007 | 5892 | 0.010 |
Why?
|
| Probability | 1 | 2004 | 2502 | 0.010 |
Why?
|
| Delayed-Action Preparations | 1 | 2002 | 965 | 0.010 |
Why?
|
| Nursing Homes | 1 | 2005 | 1034 | 0.010 |
Why?
|
| Drug Therapy | 1 | 2001 | 497 | 0.010 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2008 | 2842 | 0.010 |
Why?
|
| Cricetinae | 2 | 1978 | 2471 | 0.010 |
Why?
|
| Mice | 3 | 2014 | 81045 | 0.010 |
Why?
|
| Radiotherapy Dosage | 1 | 2004 | 2876 | 0.010 |
Why?
|
| Salvage Therapy | 1 | 2004 | 1269 | 0.010 |
Why?
|
| Pharmacogenetics | 1 | 2001 | 676 | 0.010 |
Why?
|
| Protease Inhibitors | 1 | 2001 | 790 | 0.010 |
Why?
|
| Osmolar Concentration | 2 | 1989 | 683 | 0.010 |
Why?
|
| Preoperative Care | 1 | 2006 | 2245 | 0.010 |
Why?
|
| Depression | 1 | 2016 | 7733 | 0.010 |
Why?
|
| Lipoproteins | 1 | 2002 | 876 | 0.010 |
Why?
|
| Organic Chemistry Phenomena | 2 | 1966 | 5 | 0.010 |
Why?
|
| Chemistry, Organic | 2 | 1966 | 9 | 0.010 |
Why?
|
| Vigabatrin | 1 | 1997 | 92 | 0.010 |
Why?
|
| Succinate-Semialdehyde Dehydrogenase | 1 | 1997 | 70 | 0.010 |
Why?
|
| Radiology | 1 | 2010 | 2090 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 2003 | 2372 | 0.010 |
Why?
|
| Neovascularization, Pathologic | 1 | 2007 | 2633 | 0.010 |
Why?
|
| Animals | 5 | 2014 | 168561 | 0.010 |
Why?
|
| Chemistry | 2 | 1966 | 352 | 0.010 |
Why?
|
| Hemoglobins | 1 | 2002 | 1532 | 0.010 |
Why?
|
| Chemical Phenomena | 2 | 1966 | 517 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 1994 | 19862 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2007 | 3502 | 0.010 |
Why?
|
| Muscle, Skeletal | 2 | 2004 | 4933 | 0.010 |
Why?
|
| Language Development Disorders | 1 | 1997 | 196 | 0.010 |
Why?
|
| Smoking | 1 | 2012 | 8969 | 0.010 |
Why?
|
| Metabolism, Inborn Errors | 1 | 1997 | 288 | 0.010 |
Why?
|
| Health Education | 1 | 2001 | 1053 | 0.010 |
Why?
|
| Endothelium, Vascular | 1 | 2007 | 4455 | 0.010 |
Why?
|
| Research | 1 | 1963 | 1999 | 0.010 |
Why?
|
| Growth Hormone | 1 | 1996 | 703 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2004 | 5062 | 0.010 |
Why?
|
| Progesterone | 1 | 1978 | 773 | 0.010 |
Why?
|
| Motor Skills | 1 | 1997 | 518 | 0.010 |
Why?
|
| Benzodiazepines | 1 | 1999 | 1101 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2007 | 12344 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 1988 | 19223 | 0.010 |
Why?
|
| Health Status | 1 | 2005 | 4030 | 0.010 |
Why?
|
| Comorbidity | 1 | 2005 | 10372 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2007 | 10472 | 0.010 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 1997 | 1123 | 0.010 |
Why?
|
| Models, Statistical | 1 | 2005 | 5100 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2007 | 16665 | 0.010 |
Why?
|
| Cholesterol, HDL | 1 | 1996 | 1813 | 0.010 |
Why?
|
| Myocardium | 1 | 1963 | 4775 | 0.010 |
Why?
|
| Diatrizoate | 1 | 1989 | 86 | 0.010 |
Why?
|
| Puberty | 1 | 1972 | 489 | 0.010 |
Why?
|
| Developmental Disabilities | 1 | 1997 | 1452 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2004 | 7901 | 0.000 |
Why?
|
| Liver | 1 | 1963 | 7470 | 0.000 |
Why?
|
| Lung Neoplasms | 1 | 2010 | 13019 | 0.000 |
Why?
|
| Spermatogenesis | 1 | 1986 | 262 | 0.000 |
Why?
|
| Spectrum Analysis | 1 | 1966 | 451 | 0.000 |
Why?
|
| Thyroid Gland | 1 | 1990 | 1172 | 0.000 |
Why?
|
| Biological Assay | 1 | 1986 | 652 | 0.000 |
Why?
|
| Diagnosis, Differential | 1 | 1997 | 12958 | 0.000 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2002 | 11472 | 0.000 |
Why?
|
| Mental Disorders | 1 | 1999 | 6587 | 0.000 |
Why?
|
| Child, Preschool | 3 | 1997 | 40955 | 0.000 |
Why?
|
| Ejaculation | 1 | 1978 | 58 | 0.000 |
Why?
|
| Drug Implants | 1 | 1978 | 243 | 0.000 |
Why?
|
| Heart Rate | 1 | 1989 | 4091 | 0.000 |
Why?
|
| Pregnancy | 1 | 1978 | 29087 | 0.000 |
Why?
|
| Brain | 1 | 1963 | 26343 | 0.000 |
Why?
|
| Sex Chromosomes | 1 | 1976 | 105 | 0.000 |
Why?
|
| Contrast Media | 1 | 1989 | 5295 | 0.000 |
Why?
|
| Electrocardiography | 1 | 1989 | 6440 | 0.000 |
Why?
|
| Disorders of Sex Development | 1 | 1976 | 122 | 0.000 |
Why?
|
| Infant | 1 | 1997 | 35070 | 0.000 |
Why?
|
| Sleep, REM | 1 | 1972 | 594 | 0.000 |
Why?
|
| Wakefulness | 1 | 1972 | 1243 | 0.000 |
Why?
|